Literature DB >> 20695810

Toward a more psychometrically sound brief measure of schizotypal traits: introducing the SPQ-Brief Revised.

Alex S Cohen1, Russell A Matthews, Gina M Najolia, Laura A Brown.   

Abstract

Psychometric case identification of individuals at risk for developing schizophrenia-spectrum disorders is an important enterprise. Unfortunately, current instruments for this purpose are limited. The present studies sought to improve the Schizotypal Personality Questionnaire-Brief (SPQ-Brief), a measure of schizotypal traits that has come under recent criticism. In the first study, we conducted exploratory factor analysis on the SPQ-Brief using a Likert-style scoring format in a large sample of nonclinical adults. Although acceptable internal consistency was found, the original factor structure was not supported. In the second study, we administered the full version of the SPQ to a separate large nonclinical adult sample and employed exploratory and confirmatory factor analysis to identify critical items that could be used to revise the SPQ-Brief. The end product of these studies is the SPQ-Brief Revised, which offers a subordinate seven-factor and super-ordinate three or four factor solution, employs a Likert-scale format to improve sensitivity, and is brief (34 items).

Entities:  

Mesh:

Year:  2010        PMID: 20695810     DOI: 10.1521/pedi.2010.24.4.516

Source DB:  PubMed          Journal:  J Pers Disord        ISSN: 0885-579X


  38 in total

1.  Illusory superiority and schizotypal personality: explaining the discrepancy between subjective/objective psychopathology.

Authors:  Alex S Cohen; Tracey L Auster; Rebecca K MacAulay; Jessica E McGovern
Journal:  Personal Disord       Date:  2014-08-25

2.  The P1 visual-evoked potential, red light, and transdiagnostic psychiatric symptoms.

Authors:  Jeffrey S Bedwell; Christopher C Spencer; Chi C Chan; Pamela D Butler; Pejman Sehatpour; Joseph Schmidt
Journal:  Brain Res       Date:  2018-03-03       Impact factor: 3.252

3.  The moderating effects of perceived intentionality: exploring the relationships between ideas of reference, paranoia and social anxiety in schizotypy.

Authors:  Sean C Morrison; Alex S Cohen
Journal:  Cogn Neuropsychiatry       Date:  2014-07-02       Impact factor: 1.871

Review 4.  The assessment of schizotypy and its clinical relevance.

Authors:  Oliver J Mason
Journal:  Schizophr Bull       Date:  2015-03       Impact factor: 9.306

5.  The Williams syndrome prosociality gene GTF2I mediates oxytocin reactivity and social anxiety in a healthy population.

Authors:  Tanya L Procyshyn; Jason Spence; Silven Read; Neil V Watson; Bernard J Crespi
Journal:  Biol Lett       Date:  2017-04       Impact factor: 3.703

6.  A temporal examination of co-activated emotion valence networks in schizophrenia and schizotypy.

Authors:  Alex S Cohen; Dallas A Callaway; Kyle R Mitchell; Jeff T Larsen; Gregory P Strauss
Journal:  Schizophr Res       Date:  2015-12-19       Impact factor: 4.939

7.  Schizotypal personality questionnaire--brief revised (updated): An update of norms, factor structure, and item content in a large non-clinical young adult sample.

Authors:  Charlie A Davidson; Lesa Hoffman; William D Spaulding
Journal:  Psychiatry Res       Date:  2016-02-08       Impact factor: 3.222

8.  The imprinted gene LRRTM1 mediates schizotypy and handedness in a nonclinical population.

Authors:  Emma L Leach; Gratien Prefontaine; Peter L Hurd; Bernard J Crespi
Journal:  J Hum Genet       Date:  2014-05-01       Impact factor: 3.172

9.  The normalities and abnormalities associated with speech in psychometrically-defined schizotypy.

Authors:  Alex S Cohen; Tracey L Auster; Jessica E McGovern; Rebecca K MacAulay
Journal:  Schizophr Res       Date:  2014-10-29       Impact factor: 4.939

10.  The paradox of schizotypy: resemblance to prolonged severe mental illness in subjective but not objective quality of life.

Authors:  Alex S Cohen; Tracey L Auster; Rebecca K MacAulay; Jessica E McGovern
Journal:  Psychiatry Res       Date:  2014-03-20       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.